Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation.
Limited quarterly history available
EPS needs at least three reported quarters before a meaningful chart is shown.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
N/A
EARNINGS PER SHARE (EPS) AVG 3Y
N/A
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kailera Therapeutics, Inc.
Market Cap
$1.40B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
Market Cap
$1.42B
Earnings Per Share (EPS)
0.90
TTM Avg
0.79
3Y Avg
0.56
5Y Avg
0.48
Market Cap
$1.43B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.43B
Earnings Per Share (EPS)
-5.84
TTM Avg
-6.06
3Y Avg
-7.62
5Y Avg
-6.71
Market Cap
$1.36B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.33
3Y Avg
-2.33
5Y Avg
-2.33
Market Cap
$1.45B
Earnings Per Share (EPS)
-2.74
TTM Avg
-3.05
3Y Avg
-2.66
5Y Avg
-2.66
Market Cap
$1.47B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Earnings Per Share (EPS)
1.71
TTM Avg
0.68
3Y Avg
0.58
5Y Avg
0.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -8.88 | 53.77 | 24.70 | 19.33 |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 0.90 | 0.79 | 0.56 | 0.48 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 5.37 | -2.79 | -4.06 | -3.18 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -5.84 | -6.06 | -7.62 | -6.71 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.36B | N/A | -2.33 | -2.33 | -2.33 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | -2.74 | -3.05 | -2.66 | -2.66 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 1.71 | 0.68 | 0.58 | 0.72 |
| Omeros Corporation (OMER)vs › | $1.35B | 1.72 | -1.38 | -1.54 | -1.77 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-4.21
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.26 |
